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2. Diagnosis, Investigations and Screening 
 
 
Investigation of colorectal cancer may be considered in three distinct groups: 
 
a) Initial diagnosis 
b) Staging of colorectal cancer 
c) Surveillance following completion of treatment 
 
	
 
2.1 Initial Diagnosis  
 
 
2.1.1 Process of referral and investigation 
 
Concern over a diagnosis of colorectal cancer should prompt urgent referral, in most cases within 
general practice through a ‘two week wait rule’. Criteria for two-week wait referral (National 
Institute for Health and Clinical Excellence, 2015) should be satisfied and in many institutions, 
patients are offered a ‘direct to test service’. Initial investigations are planned on the basis of 
presenting symptoms (anaemia, change in bowel habit, rectal or abdominal mass), age and co-
morbidity, as well as available local expertise and resources. A typical investigation algorithm is 
shown in Table 2.1. Patients presenting via a non-urgent route should also be investigated along 
similar lines. The NICE guidance (NG 12) for suspected colorectal cancer (National Institute for 
Health and Clinical Excellence, 2015) recommends using faecal occult blood testing for a subset 
of patients without rectal bleeding. This remains contentious due to equivocal evidence in 
symptomatic patients. Its practical implementation remains challenging in most regions. 
 
 
 
SYMPTOM Age 2WW INDICATION PLEASE 
TICK* 
DIRECT TO TEST RESULTS 
CHANGE IN 
BOWEL 
HABIT 
Over 55 Looser and/or more frequent stools, 
persistently for more than 6 weeks without 
rectal bleeding 
 Colonoscopy 
Fit for bowel prep?*  
 
 Y {  }             N {  } 
POSITIVE test (cancer) – direct 
referral to MDT via colorectal 
nurse specialists 
Or to other MDT if non-GI 
cancer e.g. ovarian 
 
NEGATIVE test (no major 
pathology) – Once cancer has 
been excluded, patient will be 
referred back to GP e.g. coeliac 
disease, gallstones, hernias etc. 
 
Only in exceptional 
circumstances where immediate 
onward referral is deemed 
clinically necessary will onward 
referral be made by the 
secondary care clinician see 
OTHER below: 
RECTAL 
BLEED 
Over 40 
 
Change in bowel habit – rectal bleeding with 
a change in bowel habit to looser and/or more 
frequent stools persistently for 6 weeks 
 
 
 
 
 
 
 Colonoscopy  
Fit for bowel prep?*  
 
 Y {  }              N {  } 
Over 55 No change in bowel habit Rectal bleeding 
persistently for  
> 6 weeks without a change in bowel habit & 
without anal symptoms 
 Flexible sigmoidoscopy 
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MASS 
All 
ages 
Rectal – A definite palpable rectal (not pelvic) 
mass 
 Flexible sigmoidoscopy  
OTHER - Any condition 
detected on investigation that 
poses imminent danger of 
deterioration or serious harm to 
the patient e.g. AAA>5cm, 
Inflammatory bowel disease, 
decompensated cirrhosis, colonic 
polyp ≥1cm, will be referred 
directly to the appropriate service. 
All 
ages 
Abdominal – A definite palpable abdominal 
mass 
 CT colonography  
or colonoscopy 
ANAEMIA 
All 
ages 
Men – of any age with unexplained iron 
deficiency 110 g/L or below 
 CT colonography 
or colonoscopy 
+ OGD 
All 
ages 
Women – non-menstruating women with 
unexplained iron deficiency anaemia 100 g/L 
or below. 
 CT colonography 
or colonoscopy  
+ OGD 
ANY OF 
ABOVE 
>75 
years 
 As above (please tick) BUT aged >75 years or 
symptoms not covered in above 
 2WW Outpatient clinic Clinic then Direct-to-Test and 
as above 
 
Table 2.1 Investigation algorithm for suspected colorectal cancer. 
 
 
Patients with suspected colorectal cancer should be referred urgently to a team specializing 
in the management of colorectal cancer. 
 
Recommendation grade D 
 
 
2.1.2 Choice of investigations 
 
The recent UK Special Interest Group in Gastrointestinal and Abdominal Radiology (SIGGAR) 
Trials (Atkin et al, 2013; Halligan et al, 2013) provides level I evidence on the choice for whole 
colon imaging in patients with symptoms suggestive of colorectal cancer. The trial comprised a 
composite single endpoint incorporating: 
 
1. CT colonography (CTC) vs. double contrast barium enema (DCBE), with detection rates of 
cancer and large polyps (≥1 cm). 
 
2. CTC vs. optical colonoscopy (OC), powered to measure the requirement for additional colonic 
tests following the randomized investigation. The rationale is that subsequent OC with biopsy 
will usually be required for CTC-suspected cancer or significant polyp, and that any benefit in 
avoiding an endoscopic procedure would be cancelled out if a CTC precipitates a large number 
of subsequent unnecessary colonoscopies. Conversely, OC is more often suboptimal, limited or 
incomplete in the more elderly symptomatic population, which may lead to further colonic 
investigations. 
 
The principal finding was that CTC detected significantly more cancers and large polyps than 
DCBE (7.3% vs. 5.6%; p=0.039). Patients randomized to CTC were diagnosed with fewer post-
test colorectal cancers than DCBE during a 3-year follow up period (3/45 vs. 12/85). No 
significant difference was found in detection rates between CTC and OC (10.7% v 11.4%) but 
CTC generated more colonic investigations than OC (relative risk 3.65). Post-test colorectal 
cancers during 3-year follow up were 1/29 for CTC and 0/55 for OC, confirming prior meta-
analysis suggesting no significant difference in sensitivity of the two tests for colorectal cancer 
(Pickhardt et al, 2011).  
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Patients with suspected colorectal cancer should be offered either optical colonoscopy or 
CT colonography. 
 
Recommendation grade A 
 
CT colonography should replace double contrast barium enema. 
 
Recommendation grade A 
 
 
2.1.3 Quality of investigations 
 
Regardless of whether OC or CTC is used, certain levels of Quality Assurance should be 
achieved by these investigations. 
 
• Colonoscopy 
Colonoscopy should be performed by an experienced colonoscopist, or a colonoscopist who has 
been certified by the Joint Advisory Group (JAG), or by trainees supervised by that above. 
National quality and safety standards for endoscopy have been set by the Department of Health 
using a Global Rating Scale (GRS) (www.grs.nhs.uk) and by the British Society for 
Gastroenterology (www.BSG.org.uk). The quality and safety indicators underpin the respective 
items using GRS.  
 
• CT Colonography (CTC)  
There are several international consensus recommendations regarding acquisition of CTC images 
(Burling, 2010; McFarland et al, 2009; Neri et al, 2013). The examination may be performed 
following full purgative bowel preparation and administration of a faecal tagging agent (oral 
contrast medium administered several hours prior to the investigation). Some faecal tagging 
agents such as sodium amidotrizoate/meglumine amidotrizoate (Gastrografin) also have a 
laxative effect and can be used as a combined cleansing/tagging agent. Although some oral 
faecal tagging agents have a laxative effect, others do not, and in particularly frail patients a 
combination of dietary manipulation and non-laxative faecal tagging (such as low-dose iso-
osmolar iodinated contrast media, or certain barium sulphate preparations) may achieve adequate 
image quality to exclude clinically relevant neoplasia. In all cases (with or without purgation), 
faecal tagging is now regarded as mandatory when performing CTC. 
 
Mechanical insufflation with CO2 reduces patient discomfort and improves colonic distension, 
when compared with room air. Intravenous antispasmodic, typically hyoscine butylbromide 
(Buscopan), also improves distension and may reduce pain. The use of intravenous contrast 
medium is not essential for colonic lesion detection, but may be an efficient strategy in patients 
in whom the pre-test probability of either colorectal cancer or important extracolonic pathology 
is high, and is invariably given when whole colon imaging and staging is required following 
detection of a cancer where OC failed to evaluate the proximal colon. 
 
All reporting radiologists must meet the recommended standards for competency, and be actively 
involved in audit of their practice and performance (British Society of Gastrointestinal and 
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Abdominal Radiology & The Royal College of Radiologists, 2014). There are specific 
stipulations for radiologists involved in the National Bowel Cancer Screening Program (NHS 
Bowel Cancer Screening Programme, 2012).  
 
Radiological and endoscopic investigations should meet national standards and be 
subjected to regular Quality Assurance.  
 
Recommendation grade C 
 
 
2.1.4 Diagnosis of colorectal cancer 
 
Colon cancer should ideally be confirmed histologically, but when a lesion with high probability 
of malignancy has been detected by CTC, histology prior to surgery is not essential if the 
segment cannot be reached endoscopically. Conversely, histological confirmation of malignancy 
should be considered mandatory in all rectal cancers when surgery might result in either a 
permanent stoma or an ultra-low anterior resection, or when neoadjuvant therapy is being 
considered. Exception to this may be a large endoluminal lesion where biopsies have been 
inconclusive and the lesion is not amenable to endoscopic surgery. 
 
Preoperative histological confirmation of colonic cancer is desirable but not essential in 
cases with high probability of malignancy based on clinical presentation and optimal 
imaging. 
 
Recommendation grade D 
 
Pre-treatment histological confirmation of rectal cancer is considered essential. Exceptions 
should be rare and are usually large lesions not amenable to endoscopic removal and 
inconclusive biopsies. 
 
Recommendation grade D 
 
 
 
2.2 Staging of Colorectal Cancer 
 
 
Staging investigations for colorectal cancer should address three areas: 
 
a) Assessment of local disease  
b) Metastatic disease  
c) Synchronous colonic disease 
 
 
2.2.1 Assessment of local disease 
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Local extent of colonic disease is assessed by abdominal and pelvic computed tomography (CT) 
to provide information on extent of spread in relation to the bowel wall and adjacent organs. This 
is essential to the planning of surgery (e.g. non-anatomical resection) and to allow consideration 
of neoadjuvant therapy when the disease is locally very advanced or unresectable. 
 
CT has limited ability to differentiate the individual layers of the bowel wall, making the 
distinction between T1 and T2 disease challenging. Although certain tumour morphology 
features seen on CT colonography, namely an arc-shaped or trapezoidal tumour configuration, 
may suggest T1 or T2 status, these are yet to be validated in a prospective, multicentre setting. 
Similarly, the distinction between T3 and T4 disease can be challenging because the latter may 
be contingent only on sub-millimetre spread through the serosa for peritonealised colon (T4a by 
TNM 7th edition; T4b by TNM 5th edition). Conversely, because of the naturally high contrast at 
CT between the bowel wall and the adjacent fat, T3 disease can usually be discriminated from 
earlier-stage lesions, with one meta-analysis suggesting a 86% sensitivity for T3 disease (Dighe 
et al, 2010). Furthermore, CT provides potentially useful preoperative prognostic information; 
tumours can be reliably split into ‘low-risk’ and ‘high-risk’ subgroups depending on depth of 
transmural spread and local lymph node status (Smith et al, 2007). However, at present there is 
insufficient evidence to recommend triage of higher risk patients for neoadjuvant treatment on 
these grounds alone, pending the results of ongoing clinical trials such as FOxTROT (EudraCT 
2007-001987-55). FOxTROT will also provide information on the accuracy of CT in the straight 
to surgery arm (Foxtrot Collaborative Group, 2012).  
 
Lymph node staging is more challenging, although in most cases involved nodes lie along the 
local vascular pedicle, which is removed with the primary. Meta-analysis suggests that CT is 
approximately 70% sensitive for the detection of nodal involvement for colonic cancers (Dighe 
et al, 2010), similar to prior meta-analysis for rectal cancers. 
 
Magnetic resonance imaging (MRI), with few exceptions such as patients with contra-indications 
to MRI or unwilling due to phobia, is recommended for local staging of rectal cancers, 
particularly to determine the risk of the circumferential margin (CRM) being involved or 
threatened by tumour. The ability of MRI to predict a clear (>1 mm) CRM in rectal cancer is 
very good (>90%) (MERCURY Study Group, 2006). However, staging of pelvic lymph nodes is 
less accurate. 
 
Cancers of the lower third of the rectum are defined on MRI as an adenocarcinoma with its lower 
edge, at or below the level of origin of the levator muscle on the pelvic side-wall (Moran 2014). 
Patients with low rectal cancers have generally worse outcomes in terms of curative (R0) 
resection, local recurrence and overall survival compared to mid and upper rectal cancers. 
Specific management issues have been identified and addressed through the LOREC program, in 
order to try to improve outcomes in this group. 
 
Rectal cancer requires specifically tailored locoregional staging since this affects the feasibility 
and timing of radical surgery, and this will be discussed further in Chapter 4. 
 
Since introduction of the UK NHS Bowel Cancer Screening Program, increasing numbers of 
early colon and rectal cancers are being diagnosed. Suspected early stage rectal cancers should 
	 7	
be assessed with endorectal ultrasound for more accurate local staging if considering patient for 
TEMS. A Significant Polyp Early Colorectal Cancer (SPECC) Program is currently underway to 
improve definition, recognition, documentation, strategic planning and treatment of these lesions 
(Pelicancancer.org.uk).   
  
 
2.2.2 Metastatic disease 
 
Colorectal cancers commonly metastasize to the liver, lungs and peritoneum. Routine staging by 
CT chest, abdomen and pelvis provides adequate staging in most cases. Further characterization 
of equivocal liver lesions may be assisted by MRI. 18-Fluorodeoxyglucose positron emission 
tomography/CT (18-FDG PET/CT) may be used to investigate suspicious lesions seen on CT or 
MRI. In addition, PET/CT provides valuable assessment to help exclude occult metastatic 
disease in patients being considered for non-anatomical resection of locally advanced cancers or 
surgical management of liver and lung metastases, to facilitate appropriate patient selection 
aiming to reduce futile procedures (Adams et al, 2013). 
 
 
2.2.3 Synchronous colonic disease 
 
Synchronous colorectal cancers are present in 2-3% of patients and a further 20% have 
synchronous significant benign lesions (diverticular disease, colitis or polyps). Synchronous 
lesions should be diagnosed at colonoscopy or CTC, as this is crucial in planning complete 
surgical resection. The most distal significant lesion in the colon should be tattooed (Williams et 
al, 2013) with the proviso that the endoscopist should ensure they are in the sigmoid and not the 
rectum. The tattoo should be placed into a saline bleb 2-5 cm from the base of the lesion on the 
distal (anal) side and the estimated distance clearly documented. More than one tattoo may be 
applied but the endoscopist should document very carefully the number and position of tattoos in 
relation to the polyp or tumour. Rectal lesions should not be tattooed. 
 
All patients with suspected colonic cancer should be staged with a CT thorax, abdomen and 
pelvis. 
 
Recommendation grade B 
 
All patients with suspected rectal cancer should be staged with a CT thorax, abdomen and 
pelvis. Patients being considered for curative locoregional treatment should have MRI of 
the pelvis. 
 
Recommendation grade B 
 
Synchronous lesions should be identified using colonoscopy or CTC prior to colorectal 
cancer resection. If complete colonoscopy is not possible, CTC should be considered. CT of 
the thorax can be combined with CTC to permit staging at the same hospital visit. 
 
Recommendation grade B 
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2.3 Colorectal Cancer Screening 
 
 
2.3.1 Screening for average risk population 
 
2.3.1.1 NHS Bowel Cancer Screening Program (BCSP)  
 
The NHS BCSP offers screening every two years to the population aged between 60-69, as over 
80% of newly diagnosed colorectal cancers occur at this age and beyond. Since 2008, the 
screening age group has been extended to 74 years old, in accordance with the government’s 
strategy to improve cancer outcomes.  
 
Screening with guaiac faecal occult blood test (FOBT) has been shown to reduce colorectal 
cancer mortality in four large population-based randomized control trials after more than 10 
years of follow up (table 4.2) (Hewitson et al, 2008). The results from the UK and Denmark 
were directly comparable. The apparently superior results in the US trial were ascribed to a far 
higher colonoscopy rate, which in turn was due to more frequent FOB testing and a lower 
positive test threshold.  
 
Study Country Screening  
frequency 
Age 
range (yr) 
Follow up 
period (yr) 
RR 95% CI 
     
Funen Denmark Annual 45-75 17 0.84 0.73-0.96 
  Biennial   0.89 0.78-1.01 
Minnesota U.S. Annual 50-80 18 0.67 0.51-0.83 
  Biennial   0.79 0.62-0.97 
Nottingham U.K. Biennial 45-74 11.7 0.87 0.78-0.97 
Goteberg Sweden Biennial 60-64 19 0.84 0.71-0.99 
 
Table 2.2. Characteristics, Relative Risk (RR) and 95% Confidence Interval (CI) for colorectal 
cancer mortality of 4 randomized controlled trials using FOBT (Hewitson et al, 2008). Yr=Year. 
 
The guaiac FOBT is being replaced with the more accurate faecal immunochemical test (FIT) 
for colorectal cancer screening programs (Halloran et al, 2012). It has shown improved uptake 
and the ability to detect significantly more colorectal cancers and advanced adenomas (Digby 
et al, 2016; Moss et al, 2016). However, the higher uptake and test positivity is likely to 
stretch colonoscopy services even further (Tinmouth et al, 2015). 
 
People with positive faecal occult blood tests (5 or 6 samples tested positive; or 1-4 samples 
positive, followed by any positive result on 2 subsequent screening kits) are offered a screening 
colonoscopy. This is carried out in endoscopy units by a JAG accredited BCSP colonoscopist. 
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For individuals unwilling to have or who cannot tolerate colonoscopy, CTC could be considered. 
Follow up colonoscopies will be determined by the results of the index colonoscopy. 
 
The NHS BCSP has had a positive impact in elective treatment of colorectal cancers by early 
cancer detection, increased use of minimally invasive techniques and reducing the need for 
emergency colorectal cancer resections. It also has had a positive impact on 30-day postoperative 
mortality and 5-year survival rates.  
 
2.3.1.2 NHS Bowel Scope Program  
 
A randomized controlled trial in the UK has shown that a ‘one-off’ screening flexible 
sigmoidoscopy reduces CRC incidence and CRC-related mortality by 23% and 31% respectively 
(Atkin et al, 2010) after a median follow up of 11 years. Results from the UK trial have 
prompted the NHS to roll out a population-based program using flexible sigmoidoscopy as 
screening offered at age 55 with the option to opt in up to aged 60 
(http://www.cancerscreening.nhs.uk/bowel/). 
 
Population-based NHS Bowel Cancer Screening Program will increase detection of early 
stage disease, improve cancer survival and reduce the need for emergency surgery. 
Establishment of flexible sigmoidoscopy screening will likely reduce incidence of distal 
cancers as well as reducing mortality. 
 
Recommendation grade A 
 
Patients diagnosed through the National Bowel Cancer Screening Program should have a 
defined pathway into their local colorectal cancer MDT. 
 
Recommendation grade D 
 
 
2.3.2 Screening for at risk population  
 
Approximately 5% of colorectal cancers are due to the high-risk familial conditions, Lynch 
syndrome and the polyposis syndromes. It is important that these familial syndromes are 
identified so that the index case and family members can be offered appropriate management. In 
a further 30% there is some familial contribution to aetiology, but the genetic factors involved 
remain unclear and the level of risk is heterogeneous. 
 
Families deemed to be at high risk of colorectal cancer should be managed through clinical 
genetic services, which should provide a robust surveillance program ensuring appropriate use of 
genetic testing, timely surveillance and counseling. 	
 
2.3.2.1 Risk stratification according to family history 
 
An accurate family history gives an empirical assessment of risk. The site and age at diagnosis of 
all cancers in family members should be documented, as well as the presence of related features 
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such as colorectal adenomas. The value of risk assessment on the basis of family history is 
limited in small families and those with poorly defined paternity. Current BSG guidelines 
(Cairns et al, 2010) give a detailed evidence base for stratifying risk level according to family 
history, and provide screening recommendations (summarised in Table 4.3): 
 
Low risk 
Individuals in this group have one of the following: 
• No confirmed family history of colorectal cancer 
• No first-degree relative (i.e. parent, sibling or child) with colorectal cancer 
• Only one first-degree relative with colorectal cancer, diagnosed at age 50 years or older 
 
Low risk individuals should be reassured, informed of the symptoms of colorectal cancer 
and encouraged to participate in the NHS Bowel Cancer Screening Program. 
 
Recommendation grade C 
 
Low-moderate risk 
This group comprises those with one of: 
• One affected relative diagnosed with colorectal cancer under 50 years 
• Two affected first-degree relatives diagnosed at age 60 years or older 
 
Low-moderate risk individuals should be offered a ‘one-off’ screening colonoscopy at the 
age of 55 years. 
 
Recommendation grade C 
 
High-moderate risk 
This group comprises those with one of:  
• Three or more relatives with colorectal cancer in a first degree kinship* (but none under 
50 years; a factor which confers high risk) 
• Two relatives diagnosed with colorectal cancer under 60 years (or with a mean age at 
diagnosis under 60 years) in a first degree kinship* 
• Both parents diagnosed with colorectal cancer under 60 years  
 
*A first-degree kinship is a family group in which each affected individual is a first degree 
relative of the others. The individual seeking screening should be a first degree relative of one of 
these affected relatives. 
 
High-moderate risk individuals should be offered colonoscopy every 5 years from the age 
of 50 to 75 years. 
 
Recommendation grade C 
 
Risk Relative Risk of CRC Colonoscopy Screening 
Low <2 None 
Low moderate 3-6 One off age 55 years 
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High moderate 5 yearly from 50 years 
 
Table 2.3. Management of individuals with low, moderate and high risk of CRC. 
 
High risk 
This category encompasses Lynch syndrome and the polyposis syndromes. Criteria for inclusion 
include: 
• Member of a family with known familial adenomatous polyposis (FAP) or other 
polyposis syndrome 
• Member of a family with known Lynch syndrome 
• Pedigree suggestive of autosomal dominantly inherited colorectal (or other Lynch 
syndrome-associated) cancer (Amsterdam criteria Table 2) 
• Pedigree indicative of autosomal recessive inheritance, suggestive of MYH associated 
polyposis (MAP) 
 
2.3.2.2 Lynch syndrome 
 
This dominantly inherited condition is due to germline mutation in one of the mismatch repair 
(MMR) genes, and carries a 50-70% lifetime risk of colorectal cancer (often developing at an 
early age), as well as increased incidence of other cancers. The cancers are characterized by 
microsatellite instability (MSI) and loss of mismatch repair (MMR) protein, detectable by 
immunohistochemical staining. There is a preponderance of mucinous and right sided cancers 
compared to sporadic colorectal cancer populations. Indications for MSI testing are increasing 
with recent evidence supporting its use in all patients with colorectal cancer (Vasen et al, 2013). 
Further analysis of methylation status and BRAF mutation can distinguish sporadic cases of MSI 
from those with a genetic predisposition. 
 
Full guidelines for the management of individuals with Lynch syndrome are available (Vasen et 
al, 2013), and anyone suspected of having it should be referred to a clinical genetics unit. 
Important points for the clinician managing these patients are: 
• Carcinogenesis is accelerated, mandating colonoscopic screening intervals of no more 
than 2 years. 
• There is evidence that aspirin significantly reduces colorectal cancer risk. 
• The risk of metachronous cancer is high, and extended colectomy should be considered 
instead of segmental colectomy for the treatment of colorectal cancer. 
• Prophylactic total abdominal hysterectomy and bilateral salphingo-oopherectomy should 
be offered to affected women who have reached the end of their reproductive life, 
especially if they are undergoing surgery for colorectal cancer. 
 
Colonoscopic surveillance for Lynch syndrome mutation carriers should commence at the 
age of 25 years and continue for every 12-24 months up to the age of 75 years or until co-
morbidity makes it clinically inappropriate.  
 
Recommendation grade B 
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In families manifesting gastric cancer as part of the phenotype, biennial upper 
gastrointestinal endoscopy should be considered from age of 50 years and continue to age 
75 years. 
 
Recommendation grade C 
 
2.3.2.3 Familial adenomatous polyposis (FAP) 
 
This dominantly inherited syndrome is characterized by the development of hundreds of 
colorectal adenomas from late childhood and results in a risk of colorectal cancer approaching 
100% by the age of 50 years. In around 20% of patient with FAP the genetic trait arises from a 
new mutation. The most important extra-colonic manifestations are duodenal and peri-ampullary 
adenomas and carcinomas, and desmoid disease. 
 
Full guidelines for the management of individuals with FAP are available (Vasen et al, 2008), 
and anyone suspected of having it should be referred to a clinical genetics unit or specialist 
polyposis registry. Important points for the clinician managing these patients are: 
 
• Genetic testing (or endoscopic screening if no mutation has been identified) should begin 
at around 12 years of age, unless the child is symptomatic. 
• Prophylactic surgery is the mainstay of management, the type and timing determined by 
genotype, phenotype and personal circumstances. 
• Lifelong follow-up is required, with annual surveillance of the retained rectum or ileo-
anal pouch.  
• Endoscopic examination of the duodenum using a side-viewing scope should start at age 
30 years and continue at intervals determined by disease severity. 
 
Annual colonoscopy should be offered to mutation carriers from diagnosis until polyp load 
indicates a need for surgery. 
 
Recommendation grade B 
 
Individuals from families where no mutation can be identified and genetic linkage analysis 
is not possible, should have annual surveillance from the age of 13-15 until age 30 years, 
and every 3 to 5 years thereafter until age 60.  
 
Recommendation grade B 
 
For individuals who have undergone either total colectomy and ileorectal anastomosis or 
proctocolectomy and ileal pouch-anal anastomosis, lifelong endoscopic annual surveillance 
of the retained rectum or anorectal cuff is recommended. 
 
Recommendation grade B 
 
Upper gastrointestinal endoscopy (using a side-viewing endoscope) at intervals determined 
by Spigelman stage for mutation carriers is recommended from age 30 years. 
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Recommendation grade C 
 
2.3.2.4 MYH-associated polyposis 
 
This recently recognized polyposis syndrome has considerable overlap with FAP, although the 
polyp burden is often considerably less, and extra-intestinal manifestations are less frequent 
(Cairns et al, 2010). Management of the colon and rectum is essentially the same as FAP, 
although some individuals with a light polyp burden can be managed endoscopically, without the 
need for prophylactic surgery. 
 
Colonoscopic surveillance is recommended every year from age 25 years for individuals 
who are bi-allelic MYH carriers (or homozygous carriers of other BER gene defects).  
 
Recommendation grade C 
 
Upper gastrointestinal endoscopy at 3 to 5 year intervals is recommended from age 30 
years.  
 
Recommendation grade C 
 
2.3.2.5 Serrated polyposis 
 
This poorly understood condition is characterized by the development of multiple hyperplastic 
polyps, sessile serrated polyps and serrated adenomas (Edelstein et al, 2013). There appears to be 
an inherited element, but the gene(s) responsible have not yet been identified and genetic testing 
is not available.  
 
Annual colonoscopy with polypectomy is advised, and colectomy may be necessary for 
polyps that cannot be managed endoscopically. First-degree relatives should have five 
yearly screening from the age of 30 years. 
 
Recommendation grade C 
 
2.3.2.6 Peutz-Jeghers syndrome 
 
This dominantly inherited syndrome results in characteristic gastrointesinal polyps, particularly 
in the small bowel, and peri-oral pigmentation (Cairns et al, 2010). The risk of gastrointestinal, 
and other cancers, is substantial. These patients should be referred to a clinical genetics unit or 
polyposis registry. 
 
A baseline colonoscopy and upper GI endoscopy (OGD) is recommended at age 8 years. If 
significant polyps are detected, endoscopy should be repeated every 3 years. If no 
significant polyps are present at baseline endoscopy, routine surveillance is repeated at age 
18, or sooner should symptoms arise, and then every 3 years. 
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Recommendation grade C 
 
Small bowel screening using video capsule endoscopy (VCE) should be performed every 3 
years, from age 8 years, or earlier if the patient is symptomatic. Magnetic resonance 
enterography (MRE) or CT enterography are reasonable alternatives in adult patients but 
CT enterography is not favoured in children due to radiation exposure. 
 
Recommendation grade C 
 
2.3.2.7 Juvenile polyposis 
 
This is a rare syndrome due to mutation in the SMAD4 or BMPR1A genes, which results in 
typical polyps, particularly in the large bowel (Cairns et al, 2010). The risk of colorectal cancer 
is in the range 10-40%, and that of gastric cancer around 25%. Management is usually by 
endoscopic polypectomy, with surveillance intervals of 1-3 years, depending on polyp burden. 
Surgery (colectomy, proctocolectomy or gastrectomy) is sometimes required. 
 
Those with a SMAD4 mutation frequently also have hereditary haemorrhagic telangectasia, so 
bleeding or anaemia may not be due to the juvenile polyps, and appropriate investigations to 
exclude associated arteriovenous malformations should be done before any general anesthetic. 
These patients should be referred to a clinical genetics unit or polyposis registry. 
 
Colonoscopic surveillance for at risk individuals and mutation carriers is recommended 
every 1 to 2 years from age 15-18 years, or earlier if the individual is symptomatic up to age 
70 years. 
 
Recommendation grade C 
 
Upper gastrointestinal surveillance is recommended every 1 to 2 years from age 25 years.  
 
Recommendation grade C 
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